Pozen Inc /NC Files (8-K) Disclosing Entry into a Material Definitive Agreement
Immediately following the closing of the Divestiture, Amendment No. 1 to the Agreement between , entered into a Second Amendment to the Agreement which permits Worrigan, the assignee of Pernix's rights under the Agreement, to further assign the Agreement without prior written consent as collateral security for the benefit of purchasers of debt ... (more)
POZEN Announces U.S. Rights For TREXIMET Have Been Acquired by Pernix Therapeutics
The previously announced transaction was contingent upon Pernix securing financing, which is now complete.
Tue Aug 12, 2014
Naples Daily News
Pharmacist: Drugs and the domino effect When I graduated from...
When I graduated from pharmacy school in 1989, I was eager to ease the world's suffering.
Thu Aug 07, 2014
POZEN Reports Second Quarter 2014 Results
As part of the expense control, the Company has reduced its R&D staff and other costs and will continue to reduce costs not required to support the ongoing business activities.
Wed Aug 06, 2014
AVANIR Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial And Business Update
"We had a great quarter across all aspects of our business. I am delighted with the positive outcome of our ANDA patent litigation, solid revenue growth of 45% year-over-year, and the positive interim data from our open label PRISM II study in PBA and COMPASS clinical trial in migraine," said , president and CEO of Avanir.
Mon Aug 04, 2014
Closing For Pernix Therapeutics, Inc. Transaction To Acquire...
Pernix Therapeutics Holdings, Inc. , a specialty pharmaceutical company, today announced that the closing of its transaction to acquire the U.S. rights to TreximetA for the acute treatment of migraine attacks with or without aura in adults has been delayed due to a short-term supply constraint for the product.
Tue Jul 22, 2014
Lupin eyes popular GSK brands
Mumbai, July 22: Lupin, India's fourth largest drug maker by sales, is eyeing some of the mature brands of GlaxoSmithKline Plc .